BackPelthos Therapeutics Overview

Pelthos Therapeutics Profit Margin

Pelthos Therapeutics (PTHS) has a profit margin of -165.24%, below the sector sector average of 21.34%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-150.08%

As of Jun 2026

Annual Profit Margin (TTM)

-165.24%

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading
Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Pelthos Therapeutics (PTHS) FAQ

The latest profit margin for PTHS is -165.24% as of June 2026. That is below the sector sector average of 21.34%. Investors often review this figure alongside Pelthos Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, PTHS currently prints -165.24% for profit margin, while the sector average sits near 21.34%. That is roughly 874.3% below the sector mean. Large gaps often invite a closer look at Pelthos Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Pelthos Therapeutics converts resources into returns. At -165.24%, PTHS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PTHS's profit margin (-165.24%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.